Focus: Mission Pharmacal is a private specialty pharmaceutical company headquartered in San Antonio, TX, focused on small molecules and consumer products across hematology, neurology, and nephrology.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
Stable — net -1 jobs in 30d
12 added, 13 removed. Backfill posture.
Mission Pharmacal is a single-product revenue story with early-stage pipeline potential, suitable for risk-tolerant candidates seeking stability through a niche franchise but limited by thin hiring and minimal near-term catalysts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Mission Pharmacal
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Mission Pharmacal's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Anchor product generating 100% of company revenue with 14+ years of patent exclusivity remaining.
Generic/consumer product beyond patent exclusivity; likely minimal revenue contributor.
Older antihistamine post-LOE; revenue not disclosed.
Generic pain/neuropathy therapy post-LOE; likely commodity pricing.
Generic iodine product post-LOE; competitive generic market.
NDA-formulated potassium iodide nearing loss of exclusivity.
Emergency preparedness product; niche but stable demand in regulated channels.
Generic iodide formulation post-LOE; mature/declining revenue.
2 discontinued, 2 duplicate formulations not shown
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo